UPDATE: AbbVie (ABBV) Guides Q3 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AbbVie (ABBV) Tops Q2 EPS by 2c
July 24, 2015 7:53 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $1.08, $0.02 better than the analyst estimate of $1.06. Revenue for the quarter came in at $5.48 billion versus the consensus estimate of $5.62 billion.
Key Events from the Second Quarter
On May 26, AbbVie successfully completed the acquisition of Pharmacyclics, accelerating AbbVie's clinical and commercial presence in oncology. The acquisition aligns strategically to AbbVie's business model, strengthening the company's already robust oncology pipeline and further diversifying AbbVie's revenue base.AbbVie announced that the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option specifically... More